Physician profile
Annie Vu
NPI 1336738046
$15,506.40
in general payments reported to CMS, 2019-2025
63 companies · $8,318 in 2025
The $8,318 reported for 2025 was more than what 99% of Physician Assistant providers received nationally (typical 2025 total: $183).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2023: $918 · 2024: $6,270 · 2025: $8,318.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $14K · Long Term Medical Supply Or Device Loan: $698 · Education: $507.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $14,301.72 |
| Long Term Medical Supply Or Device Loan | $697.90 |
| Education | $506.78 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novartis Pharmaceuticals Corporation | $1,597.21 | 2023-2025 | |
| E.R. Squibb & Sons, L.L.C. | $1,392.69 | 2024-2025 | Reblozyl, Opdivo, Opdualag |
| Astrazeneca Pharmaceuticals LP | $983.92 | 2023-2025 | Imfinzi, Calquence, Lynparza |
| Janssen Biotech, INC. | $898.29 | 2023-2025 | Rybrevant, Erleada, Tecvayli |
| Incyte Corporation | $665.00 | 2023-2025 | Jakafi, Monjuvi, Zynyz |
| Merck Sharp & Dohme LLC | $581.30 | 2024-2025 | Keytruda, Welireg, Keytruda Qlex |
| Eisai INC. | $571.94 | 2023-2025 | |
| Takeda Pharmaceuticals U.S.A., INC. | $558.14 | 2023-2025 | Fruzaqla, Alunbrig, Iclusig |
| Astellas Pharma US INC | $466.47 | 2023-2025 | Xtandi, Vyloy, Padcev |
| Abbvie INC. | $466.08 | 2024-2025 | |
| Daiichi Sankyo INC. | $408.56 | 2023-2025 | Enhertu, Datroway, Vanflyta |
| Celgene Corporation | $395.45 | 2024-2025 | Reblozyl, Opdivo |
| Regeneron Healthcare Solutions, INC. | $365.41 | 2024-2025 | Libtayo |
| Puma Biotechnology, INC. | $361.24 | 2023-2025 | |
| Seagen INC. | $324.26 | 2023-2025 | Padcev |
Show all 63 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Genentech USA, INC. | $305.57 | 2024-2025 | Phesgo, Polivy, Tecentriq |
| Exelixis INC. | $264.35 | 2024-2025 | Cabometyx |
| Pfizer INC. | $262.99 | 2024-2025 | |
| Aveo Pharmaceuticals, INC. | $262.82 | 2024-2025 | |
| Sobi, INC | $254.29 | 2024-2025 | |
| Bayer Healthcare Pharmaceuticals INC. | $244.00 | 2024-2025 | |
| Emd Serono, INC. | $235.76 | 2024-2025 | |
| Genzyme Corporation | $222.65 | 2023-2025 | |
| Agios Pharmaceuticals, INC. | $217.68 | 2023-2024 | Pyrukynd |
| Karyopharm Therapeutics INC. | $211.30 | 2024-2025 | Xpovio |
| Coherus Oncology, INC. | $211.05 | 2023-2025 | Loqtorzi, Udenyca |
| Alexion Pharmaceuticals, INC. | $170.84 | 2024-2025 | Ultomiris |
| Lilly USA, LLC | $158.97 | 2023-2025 | Jaypirca, Verzenio, Retevmo |
| Beone Medicines USA, INC. | $153.14 | 2025 | Brukinsa, Tevimbra |
| Taiho Oncology, INC. | $150.14 | 2024-2025 | |
| Array Biopharma INC | $149.80 | 2024-2025 | Braftovi, Mektovi, Tukysa |
| Syndax Pharmaceuticals, INC. | $143.98 | 2025 | |
| Gilead Sciences, INC. | $128.33 | 2024-2025 | Trodelvy |
| Csl Behring | $116.03 | 2024-2025 | Idelvion, Afstyla |
| Ipsen Biopharmaceuticals, INC | $113.02 | 2024-2025 | Somatuline Depot, Onivyde |
| Boehringer Ingelheim Pharmaceuticals, INC. | $103.13 | 2023-2024 | Gilotrif |
| Glaxosmithkline, LLC. | $100.56 | 2024-2025 | Jemperli, Zejula, Ojjaara |
| Genmab U.S., INC. | $92.68 | 2024-2025 | Epkinly |
| Stemline Therapeutics INC. | $92.13 | 2024-2025 | Orserdu |
| Jazz Pharmaceuticals INC. | $89.17 | 2024-2025 | |
| Iovance Biotherapeutics, INC. | $88.36 | 2025 | Amtagvi |
| Immunocore Limited | $79.69 | 2024 | Kimmtrak |
| Pharmacosmos Therapeutics INC. | $76.67 | 2025 | Monoferric |
| Adc Therapeutics America, INC. | $76.24 | 2024-2025 | |
| Beigene USA, INC. | $74.45 | 2023-2024 | Brukinsa |
| Recordati_rare_diseases_inc. | $72.66 | 2024-2025 | Sylvant, Enjaymo |
| Pharmaessentia USA Corporation | $56.95 | 2024-2025 | Besremi |
| Amgen INC. | $55.62 | 2023-2025 | Blincyto, Kyprolis |
| Geron Corporation | $54.22 | 2025 | Rytelo |
| Kite Pharma, INC. | $51.56 | 2024-2025 | Yescarta |
| Servier Pharmaceuticals LLC | $35.29 | 2023-2025 | |
| Tempus Ai, INC | $28.83 | 2024 | |
| Legend Biotech USA INC. | $28.40 | 2024 | |
| Apellis Pharmaceuticals, INC. | $26.51 | 2024 | Empaveli |
| Adaptive Biotechnologies Corporation | $26.29 | 2024 | Clonoseq |
| Ge Healthcare | $25.47 | 2025 | |
| Accord Healthcare, INC. | $24.93 | 2025 | |
| Springworks Therapeutics, INC. | $24.89 | 2024 | Ogsiveo |
| Kyowa Kirin, INC. | $24.49 | 2024 | Poteligeo |
| Rigel Pharmaceuticals, INC. | $23.51 | 2025 | Gavreto, Tavalisse, Rezlidhia |
| Caris Mpi, INC. | $22.92 | 2025 | Mi Cancer Seek |
| Acrotech Biopharma INC. | $20.23 | 2024 | Beleodaq |
| Morphosys, US INC. | $17.88 | 2023 | Monjuvi |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Annie Vu listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.